AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
-0.63%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$145M
AUM Growth
+$145M
(+43%)
Cap. Flow
+$38.3M
Cap. Flow
% of AUM
26.41%
Top 10 Holdings %
Top 10 Hldgs %
24.02%
Holding
223
New
58
Increased
34
Reduced
85
Closed
14
Top Buys
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$6.33M |
| 2 |
Centene
CNC
|
$3.16M |
| 3 |
Invesco QQQ Trust
QQQ
|
$2.81M |
| 4 |
Invesco NASDAQ 100 ETF
QQQM
|
$2.81M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$2.46M |
Top Sells
| 1 |
NYMT
New York Mortgage Trust
NYMT
|
$4.22M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
$3.01M |
| 3 |
PennyMac Financial
PFSI
|
$1.76M |
| 4 |
AirSculpt Technologies
AIRS
|
$1.33M |
| 5 |
Starwood Property Trust
STWD
|
$1.19M |
Sector Composition
| 1 | Healthcare | 56.03% |
| 2 | Real Estate | 10.47% |
| 3 | Financials | 4.37% |
| 4 | Energy | 4.28% |
| 5 | Technology | 2.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 1-3 Year Treasury Bond ETF
SHY
$24.5B
| $6.33M | 4.37% | +76,992 | New | +$6.33M |
|
2
Rithm Capital
RITM
$6.57B
| $3.93M | 2.71% | 491,699 | – | – |
|
3
Galapagos
GLPG
$2.07B
| $3.55M | 2.45% | 92,000 +49,500 | +116% | +$1.91M |
|
|
4
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.5M | 2.41% | 419,500 +294,500 | +236% | +$2.46M |
|
|
5
Centene
CNC
$14.3B
| $3.16M | 2.18% | +50,000 | New | +$3.16M |
|
|
TSVT
6
DELISTED
2seventy bio
TSVT
| $3.09M | 2.13% | 302,500 +122,500 | +68% | +$1.25M |
|
7
GSK
GSK
$79.9B
| $2.85M | 1.96% | 80,000 +19,000 | +31% | +$676K |
|
|
8
Invesco QQQ Trust
QQQ
$364B
| $2.81M | 1.94% | +8,749 | New | +$2.81M |
|
|
9
Invesco NASDAQ 100 ETF
QQQM
$58.8B
| $2.81M | 1.94% | +21,262 | New | +$2.81M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.78M | 1.92% | 25,500 | – | – |
|
|
EFC
11
Ellington Financial
EFC
$1.36B
| $2.44M | 1.69% | 200,171 +35,017 | +21% | +$428K |
|
12
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $2.42M | 1.67% | 354,500 +167,000 | +89% | +$1.14M |
|
13
Mr. Cooper
COOP
$12.1B
| $2.33M | 1.61% | 56,790 | – | – |
|
14
Harmony Biosciences
HRMY
$2.12B
| $2.2M | 1.52% | +67,500 | New | +$2.2M |
|
15
Arcutis Biotherapeutics
ARQT
$1.86B
| $2.09M | 1.44% | 190,000 +111,500 | +142% | +$1.23M |
|
16
Innoviva
INVA
$1.29B
| $2.07M | 1.43% | 184,000 +109,000 | +145% | +$1.23M |
|
17
Elanco Animal Health
ELAN
$9.12B
| $2.02M | 1.39% | 215,000 +112,500 | +110% | +$1.06M |
|
18
Lantheus
LNTH
$3.73B
| $1.9M | 1.31% | 23,000 +6,000 | +35% | +$495K |
|
|
MFA
19
MFA Financial
MFA
$1.05B
| $1.72M | 1.19% | 173,425 +15,195 | +10% | +$151K |
|
|
NYMT
20
New York Mortgage Trust
NYMT
$652M
| $1.71M | 1.18% | 172,079 -423,652 | -71% | -$4.22M |
|
21
Bio-Rad Laboratories Class A
BIO
$8.06B
| $1.63M | 1.12% | 3,400 | – | – |
|
22
Neurocrine Biosciences
NBIX
$13.8B
| $1.57M | 1.08% | +15,500 | New | +$1.57M |
|
23
ADC Therapeutics
ADCT
$345M
| $1.48M | 1.02% | 760,000 +462,500 | +155% | +$902K |
|
24
Pacira BioSciences
PCRX
$1.2B
| $1.47M | 1.01% | 36,000 +17,000 | +89% | +$694K |
|
25
AdaptHealth
AHCO
$1.28B
| $1.45M | 1% | +116,500 | New | +$1.45M |
|